Research in contextEvidence before this studySevere acute respiratory syndrome coronavirus 2 infection resulting in coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in December 2019 and has become a pandemic with increasing global morbidity and mortality resulting from complications such as acute respiratory distress syndrome and pneumonia. Patients with severe COVID-19 have elevated levels of inflammatory cytokines, including interleukin-6, and acute phase reactants indicative of an exacerbated inflammatory response typical of cytokine release syndrome (CRS). We searched PubMed from database inception to March 28, 2020, using the terms 'tocilizumab AND (coronavirus OR 'severe acute respiratory syndrome coronavirus')' and did not identify any studies.Added value of this studyThis retrospective observational study from a hospital in Cosenza, Italy, is the first report on subcutaneous tocilizumab for the treatment of CRS in patients with COVID-19. We observed that there was no incidence of grade 4 CRS 7 days after these patients with severe COVID-19 received subcutaneous tocilizumab treatment. All patients demonstrated improvement of lung manifestations on follow-up chest computed tomography within 7 to 10 days after tocilizumab treatment.Implications of all the available evidenceSubcutaneous tocilizumab therapy is a promising option for the treatment of CRS in patients with COVID-19. These results support investigation of tocilizumab in the treatment of COVID-19 in randomised controlled trials.Alt-text: Unlabelled box

1. Introduction {#sec0004}
===============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated disease, coronavirus disease 2019 (COVID-19), first identified in Wuhan, China, in December 2019 [@bib0001], [@bib0002], [@bib0003], [@bib0004], is characterised as a pandemic by the World Health Organization, and global morbidity and mortality are increasing [@bib0005]. Severe complications of COVID-19 include acute respiratory distress syndrome and pneumonia, resulting in hospitalisation, severe burden on intensive care units, and high mortality rates [@bib0002]. There is no effective treatment for COVID-19 [@bib0002]. A trial of antiretroviral therapy with lopinavir-ritonavir in patients hospitalised with COVID-19 did not demonstrate a benefit beyond standard care [@bib0006].

Patients with severe symptoms of COVID-19 have elevated markers of an exacerbated inflammatory response, in contrast to those who have mild symptoms, and elevated levels of the acute phase reactant C-reactive protein and the inflammatory cytokine interleukin-6, indicative of cytokine release syndrome (CRS) \[[@bib0007],[@bib0008]\]. Furthermore, it has been reported that homeostasis of the immune system is integral in the development of pneumonia in patients with severe COVID-19 [@bib0009]. CRS is a severe or life-threatening systemic inflammatory reaction that occurs in some diseases and in response to certain therapies \[[@bib0010],[@bib0011]\]. Low-grade or mild cases of CRS can present as fever and flu-like symptoms and are treated symptomatically; however, severe CRS (grade 3 or 4) requires hospitalisation and immediate treatment [@bib0010], and progression to grade 4 CRS is life-threatening with patients requiring ventilation support and/or experiencing organ toxicity [@bib0012]. CRS is characterised by a rapid and substantial increase in cytokines, including interleukin-6, a potent inflammatory mediator [@bib0013]. CRS is a potentially fatal adverse effect of cancer immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy [@bib0014], and it is also associated with severe viral infections \[[@bib0010],[@bib0015]\]. Respiratory symptoms and acute lung injury are common in patients with CRS and can progress to acute respiratory distress syndrome, as has been shown in SARS-CoV and influenza virus infection \[[@bib0010],[@bib0011]\].

Tocilizumab is an anti--interleukin-6 receptor monoclonal antibody that blocks interleukin-6--mediated signalling and reduces markers of inflammation [@bib0016]. Tocilizumab is indicated for the treatment of chronic inflammatory disorders, including rheumatoid arthritis as intravenous dosing based on body weight or as 162 mg subcutaneous dosing, and is approved by the United States Food and Drug Administration (FDA) for the treatment of CAR T-cell--induced CRS for intravenous use \[[@bib0017],[@bib0018]\]. Interleukin-6 has been identified as a key cytokine in the exacerbated immune response in patients with severe COVID-19, and interleukin-6 levels correlate with the severity of pneumonia (Zhou et al., 2020, unpublished data) [@bib0019]. A retrospective observational study of 21 patients conducted in China investigated the effectiveness of tocilizumab in patients with severe and critical COVID-19 [@bib0020]. In that study, all patients had improved within a few days of intravenous tocilizumab treatment, oxygen intake was lowered in 15 of 20 (75%) evaluable patients, and one patient did not require any oxygen therapy; in addition, computed tomography (CT) scans revealed that lung lesion opacity had been absorbed in 19 patients (90%). This suggests that tocilizumab treatment effectively attenuated clinical symptoms and suppressed deterioration in patients with severe COVID-19, providing a potential new therapeutic strategy. Case studies and retrospective cohort analyses have reported on the use of intravenous tocilizumab in the treatment of patients with COVID-19--associated pneumonia, with results showing rapid improvement in inflammation, clinical symptoms, and lung function after the addition of tocilizumab to the treatment regimen [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025]. A randomised controlled clinical trial of intravenous tocilizumab for the treatment of COVID-19 pneumonia is underway in China (ChiCTR2000029765) [@bib0026], and the FDA has approved a randomised controlled trial of intravenous tocilizumab in patients with severe COVID-19 pneumonia in the United States (ClinicalTrials.gov, NCT04320615) [@bib0027].

We conducted a retrospective observational study of patients admitted to hospital with COVID-19 and treated with subcutaneous tocilizumab to investigate the incidence CRS.

2. Patients and methods {#sec0005}
=======================

2.1. Patients {#sec0006}
-------------

Patients aged 18 years or older with laboratory-confirmed COVID-19 admitted to the infectious diseases unit of the Annunziata Hospital in Cosenza, Italy, through March 7, 2020, who received subcutaneous tocilizumab 162 mg at the discretion of the treating physician were included in this retrospective observational study. Demographic, clinical, treatment history, and laboratory data were extracted from electronic medical records and reviewed by Giuliana Guadagnino, MD, of the Annunziata Hospital. Severe COVID-19 disease was confirmed by the presence of at least one of the following: respiratory rate ≥30/min; blood oxygen saturation ≤93%; ratio of partial pressure of oxygen in arterial blood to the inspired oxygen fraction (PaO~2~FiO~2~) \<300; lung infiltrates present on \>50% of the lung field. CRS was determined according to the presence of clinical signs and symptoms ([Table 1](#tbl0001){ref-type="table"}), and its severity was assessed based on a previously described revised grading system [@bib0012]. All patients provided written informed consent.Table 1Clinical signs and symptoms used in the grading of CRS.Table 1Organ systemSymptomsConstitutionalFever (± rigors), malaise, fatigue, anorexia, myalgias, arthralgias, nausea, vomiting, headacheSkinRashGastrointestinalNausea, vomiting, diarrheaRespiratoryTachypnea, hypoxemiaCardiovascularTachycardia, widened pulse pressure, hypotension, increased cardiac output (early), potentially diminished cardiac output (late)CoagulationElevated D-dimer, hypofibrinogenemia (± bleeding)RenalAzotemiaHepaticTransaminitis, hyperbilirubinemiaNeurologicHeadache, mental status changes, confusion, delirium, word finding difficulty or frank aphasia, hallucinations, tremor, dysmetria, altered gait, seizures[^1][^2]

2.2. Assessments {#sec0007}
----------------

The primary assessment was observation of the incidence of grade 4 CRS after tocilizumab treatment in patients with COVID-19 pneumonia, and the primary response was no incidence of grade 4 CRS. CRS was assessed according to a four-tier revised grading system with a proactive algorithm to guide the treatment of CRS based on severity that was designed to administer early immunosuppression therapy for cancer patients after adoptive T-cell therapies [@bib0012].

Routine blood samples were obtained to examine blood count, coagulation profile, serum biochemical tests (including kidney and liver function tests, creatine kinase, lactate dehydrogenase, and electrolytes), myocardial enzymes, and levels of interleukin-6, ferritin, and procalcitonin. Chest CT was performed for all patients as frequently as warranted according to the treating physician. Follow-up CT images were obtained for all patients within 7--10 days of tocilizumab treatment. Chest radiographs were evaluated by one of the authors (AZ) for the presence of ground-glass opacities, consolidation, nodules, pleural effusion, thoracic lymphadenopathy (defined as lymph nodes of abnormal size or morphology), or underlying lung disease such as emphysema or fibrosis; number of lobes affected by ground-glass or consolidative opacities; degree of lobe involvement and overall lung 'total severity score'; or evidence of any other thoracic abnormalities. Lung severity score was assessed using the Brescia-COVID respiratory severity scale (BCRSS) and algorithm [@bib0028]. The BRCSS is a stepwise approach to managing COVID-19 in patients based on clinical severity. It was developed in Brescia, Italy, in response to the COVID-19 crisis and has not yet been validated or tested in other populations. Lung involvement was assessed using a chest CT severity score (CT-SS) [@bib0029] based on the initial scans obtained at presentation. The CT-SS uses lung opacification as a surrogate for extension of the disease in the lungs. Electrocardiography was performed daily in patients whose initial QT intervals were 450 to 500 milliseconds at presentation.

2.3. Role of funding {#sec0008}
--------------------

The authors did not receive any funding for this study. Support for third-party medical writing assistance was provided by F. Hoffmann-La Roche Ltd.

3. Results {#sec0009}
==========

3.1. Patient characteristics and clinical presentation {#sec0010}
------------------------------------------------------

Twelve patients---eight men and four women---were included in this retrospective observational study; the total follow-up time was 4 weeks ([Table 2](#tbl0002){ref-type="table"}) and the median length of stay in hospital was 24 days. The median (range) age of patients was 58 (48 to 72) years. All patients had at least one comorbidity, predominantly hypertension (six patients), diabetes (five patients), and chronic obstructive lung disease (four patients). The most common symptoms of COVID-19 on hospital admission were fever, cough, and fatigue, which were present in all patients. All patients had impaired oxygen status and CRS grade 1 to 3 at presentation. Markers of inflammation were elevated above normal levels, including CRP (median, 150 mg/L), fibrinogen (median, 850 mg/dl), D-dimers (median, 18.4 mg/L), and interleukin-6 (150 pg/ml) ([Table 2](#tbl0002){ref-type="table"}).Table 2Patient demographics and clinical characteristics upon presentation.Table 2CharacteristicsAll patients *N* = 12Male, n (%)8 (66·7)Female, n (%)4 (33·3)Age, years, median (range)58 (48--72)Comorbidity, n (%)12 (100) Hypertension6 (50) Diabetes5 (41·7) Chronic obstructive lung disease4 (33)Symptoms, n (%) Fever12 (100) Cough12 (100) Fatigue12 (100)Lymphocytopenia,[a](#tb2fn1){ref-type="table-fn"} n (%)12 (100)Vitamin D deficiency, n (%)12 (100)Oxygen status, n (%) Respiratory rate ≥30 breaths/min12 (100) Blood oxygen saturation ≤93%12 (100) PaO~2~FiO~2~ \<300 mm Hg12 (100)CRS, n (%) Grade 12 (16·7) Grade 25 (41·7) Grade 35 (41·7) Grade 40Inflammatory markers, median CRP, mg/L150 Normal: \<10 Fibrinogen, mg/dl850 Normal: 150--450 LDH, U/L950 Normal: 50--248 D-dimer, mg/L18·4 Normal: 0·0--0·5 Ferritin, ng/ml1750 Normal: 11--307 Procalcitonin, ng/ml0·17 Normal: ≤0·15 Interleukin-6, pg/ml150 Normal: 0·5--5 Haptoglobin, mg/dl570 Normal: 30--200[^3][^4]

3.2. Treatment {#sec0011}
--------------

All patients were treated with antibiotics (azithromycin 500 mg/day), antivirals (lopinavir/ritonavir, eight patients; darunavir/cobicistat, four patients), and hydroxychloroquine (400 mg at suspicion/diagnosis followed by 400 mg after 12 h and 200 mg twice daily thereafter until day 5). Seven patients received high-flow nasal cannula oxygen therapy and five patients received non-invasive mechanical ventilation.

All patients received subcutaneous tocilizumab treatment for CRS; two patients received a single daily dose (two 162-mg doses resulting in a total dose of 324 mg), and ten patients received multiple doses (two 162-mg doses at baseline \[324 mg\] followed by two 162-mg doses after 24--72 h \[324 mg\]).

3.3. Cytokine release syndrome {#sec0012}
------------------------------

At presentation, two patients had grade 1 CRS, five patients had grade 2 CRS, five patients had grade 3 CRS, and no patients had grade 4 CRS. Eight patients had CRS for 0--4 days and four had CRS for longer than 4 days. Among seven patients who received high-flow nasal cannula oxygen therapy, three had grade 1 CRS and four had grade 2 CRS. All five patients who received non-invasive mechanical ventilation had grade 3 CRS. All patients received subcutaneous tocilizumab for the treatment of CRS.

There was no incidence of grade 4 CRS by day 7 in any of the 12 patients (100%) after they received tocilizumab treatment. Additional analysis showed that five patients (42%) had no incidence of grade 4 CRS by day 2 after they received tocilizumab treatment. Median serum levels of inflammatory markers, including C-reactive protein and interleukin-6, were elevated at presentation, before tocilizumab treatment (150 mg/L and 150 pg/ml, respectively; [Table 2](#tbl0002){ref-type="table"}), and were markedly improved after tocilizumab treatment (25 mg/L and 8.1 pg/ml, representing a decrease of 125 mg/L and 142 pg/ml, respectively; [Table 3](#tbl0003){ref-type="table"}).Table 3Serum markers of inflammation after tocilizumab treatment.Table 3Inflammatory markerAfter tocilizumab[a](#tb3fn1){ref-type="table-fn"}*N* = 12Decrease from presentation *N* = 12CRP, mg/L25125Normal: \<10Fibrinogen, mg/dl299551Normal: 150--450LDH, U/L299651Normal: 50--248D-dimer, mg/L0·4617·94Normal: 0·0--0·5Ferritin, ng/ml5501200Normal: 11--307Procalcitonin, ng/ml0·050·12Normal: ≤0·15Interleukin-6, pg/ml8·1141·9Normal: 0·5--5Haptoglobin, mg/dl180390Normal: 30--200[^5][^6][^7]

3.4. Oxygen status {#sec0013}
------------------

At presentation in all patients, the respiratory rate was ≥30 breaths per minute, resting state oxygen saturation was ≤93%, and PaO~2~FiO~2~ was ≤300. Within 2--7 days of receiving tocilizumab treatment, the oxygen status of each patient normalised; respiratory rate was \<30 breaths per minute, oxygen saturation was \>93%, and PaO~2~FiO~2~ was \>300.

3.5. Chest CT imaging {#sec0014}
---------------------

CT imaging at presentation revealed bilateral lung involvement with diffusely distributed peripheral and subpleural lesions. The predominant pattern was ground-glass opacity with ill-defined margins, air bronchograms, smooth or irregular interlobular or septal thickening, and thickening of the adjacent pleura. Follow-up CT images obtained 7--10 days after treatment with subcutaneous tocilizumab 162 mg showed radiographic improvement in all patients. Representative radiographs from three patients are shown in [Fig. 1](#fig0001){ref-type="fig"}.Fig. 1Representative chest radiographs from high-resolution CT scans at presentation (A) and after tocilizumab treatment (B) in three patients. At hospital admission, all patients had suspected COVID-19 and underwent high-resolution multidetector or conventional CT of the chest. Initial CT performed at presentation (A) showed alveolar and interstitial ground-glass opacities and areas of consolidation compatible with interstitial pneumonia indicative of COVID-19 infection and no evidence of pleural effusion. CT performed after tocilizumab treatment showed reduction of ground-glass opacities in all patients and reduction in areas of consolidation in some patients. CT, computed tomography.Fig 1

3.6. Safety {#sec0015}
-----------

There were no reports of adverse events attributable to subcutaneous tocilizumab treatment in this study. No changes in liver function test results were reported (no patients had elevated levels of alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]), and none of the patients experienced neutropenia. No patients experienced adverse events related to elevated serum levels of triglycerides or low-density lipoprotein. There was no evidence of latent tuberculosis infection. One patient who tested negative for hepatitis B surface antigen but positive for hepatitis B core antibody and for hepatitis B surface antigen antibody received preventive antiviral therapy with lamivudine. No patient died. There was no documented interaction of tocilizumab with antivirals, hydroxychloroquine, or corticosteroids.

4. Discussion {#sec0016}
=============

Patients with severe COVID-19 are at risk for CRS [@bib0008]. Based on the use of tocilizumab for the treatment of CAR T-cell--induced CRS, we hypothesised that patients with COVID-19 who experienced CRS would have improved clinical outcomes, such as reduced systemic inflammation, and improved measures of respiratory distress or failure if treated with subcutaneous tocilizumab. In this retrospective observational study of 12 patients with severe COVID-19 pneumonia treated with subcutaneous tocilizumab in a hospital in Italy, we observed a stable reduction in disease activity after 1 week, as determined by CRS grade. Rapid and sustained reduction in inflammatory markers, C-reactive protein, fibrinogen, lactate dehydrogenase, D-dimer, serum ferritin, procalcitonin, and interleukin-6 levels was also observed, and all patients showed radiographic improvement on chest CT. Therefore, our study demonstrates the potential for pre-emptive tocilizumab treatment to decrease CRS and to improve pulmonary outcomes in patients with severe COVID-19.

None of the patients observed in our study experienced adverse events attributable to tocilizumab treatment; there were no reported events of elevated lipid levels, ALT, or AST, as has been documented in patients with rheumatoid arthritis treated with subcutaneous tocilizumab \[[@bib0030],[@bib0031]\]. Decreased levels of circulating neutrophils have been reported following tocilizumab treatment \[[@bib0032],[@bib0033]\], but we did not observe any evidence of neutropenia after tocilizumab treatment in our study.

Current management of COVID-19 is supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death as identified in a retrospective multicentre study of 150 confirmed cases of COVID-19 in Wuhan, China [@bib0007]. Predictors of fatality in this study included elevated ferritin (mean, 1297·6 ng/ml in 68 non-survivors vs 614·0 ng/ml in 82 survivors; *p* \< 0·001) and interleukin-6 (mean, 11.4 ng/ml in non-survivors and 6.8 ng/ml in survivors; *p* \< 0·001) [@bib0007], suggesting that mortality might be influenced by the exacerbated inflammatory response to SARS-CoV-2 infection [@bib0008].

Our results showing improvement in CRS grade and CT imaging results in all patients with severe COVID-19 treated with subcutaneous tocilizumab support those from a study in China in which 19 of 21 patients with severe COVID-19 who received treatment with intravenous tocilizumab 400 mg had improved findings on chest CT radiography, recovered, and were discharged from the hospital [@bib0020]. The patients observed in our study received subcutaneous dosing of tocilizumab 162 mg either as single or multiple doses, rather than the approved intravenous dosing, because the intravenous formulation was not available. Comparability between the subcutaneous and intravenous formulations of tocilizumab has been confirmed in patients with rheumatoid arthritis in the real-world setting, and the subcutaneous formulation can provide a more convenient administration option [@bib0034]. Pharmacokinetic and pharmacodynamic analysis has demonstrated that the pharmacodynamic effect of tocilizumab occurs independently of route of administration \[[@bib0035],[@bib0036]\], and clinical studies in patients with rheumatoid arthritis have shown comparability of efficacy and safety between the subcutaneous and intravenous formulations \[[@bib0031],[@bib0037]\]. We did not observe any new safety concerns in this study of subcutaneous tocilizumab in patients with COVID-19 and CRS.

Our CT image evaluations before tocilizumab treatment were consistent with observations from a single-centre study in China of 63 patients with COVID-19 pneumonia that identified multilobe involvement and ground-glass opacity, distributed subpleurally in most patients, as the predominant presentation [@bib0038]. A larger observational study of 1099 patients from 552 hospitals in China also found that ground-glass opacity was the most common pattern in chest radiographs from patients with COVID-19 who underwent CT on hospital admittance [@bib0039].

Limitations of our study include lack of a control group in this retrospective cohort analysis and lack of information on certain disease characteristics, such as levels of proinflammatory cytokines other than interleukin-6 and viral shedding. Evaluation of CT scans was performed by one of the authors, and the results should be interpreted with the acknowledgement that no independent review was performed. All patients in our study had received treatment with antibiotics, antivirals, and hydroxychloroquine at the suspicion or diagnosis of COVID-19 and before the administration of tocilizumab. Therefore, although rapid improvement was observed after the administration of tocilizumab, it is not possible to attribute the results to a direct effect of tocilizumab. Further studies are needed to determine whether the findings can be applied to the general population of patients with severe COVID-19. Other case/cohort studies that report rapid improvement after tocilizumab treatment used the intravenous formulation at various doses in the range of 4--8 mg/kg [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025]; therefore, comparison of our findings with the findings of these studies is limited, and more data on the use of subcutaneous tocilizumab in patients with COVID-19 are needed. There is an unmet need for controlled clinical trial data to determine whether tocilizumab is effective for the treatment of COVID-19--induced pneumonia. A review of the literature did not identify any clinical trials of subcutaneous tocilizumab for the treatment of CRS in patients with COVID-19. However, clinical trials are underway in China (ChiCTR2000029765), Italy (ClinicalTrials.gov, NCT04317092 and NCT04315480), and the United States (ClinicalTrials.gov NCT04320615).

In conclusion, our findings suggest that with careful patient selection, the benefit/risk ratio for subcutaneous tocilizumab treatment in patients with severe COVID-19 is promising for rapid and sustained reduction in disease activity, improved respiratory function, and reduced pulmonary structural damage. Given the results observed in our study, other early results reported in patients with severe COVID-19 treated with tocilizumab, and the current lack of effective treatments, the results of clinical trials are eagerly awaited to confirm the efficacy of tocilizumab for the treatment of patients with COVID-19 pneumonia.
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[^1]: Republished with permission of American Society of Hematology from Lee DW et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014; **124**: 188--95. Permission conveyed through Copyright Clearance Center, Inc.

[^2]: CRS, cytokine release syndrome.

[^3]: CRP, C-reactive protein; CRS, cytokine release syndrome; PaO~2~FiO~2~, ratio of partial pressure of oxygen in arterial blood to the inspired oxygen fraction; LDH, lactate dehydrogenase; mm Hg, millimetres of mercury.

[^4]: Common Terminology Criteria for Adverse Events grade 3 or grade 4 lymphocyte count decrease (\<0·05 to \<0·2 × 10^9^/L).

[^5]: All data are shown as median values.

[^6]: CRP, C-reactive protein; LDH, lactate dehydrogenase.

[^7]: Laboratory parameters could have been measured at different times after tocilizumab treatment.
